FAQ: BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor
Summary
BetterLife Pharma has appointed Doug Drysdale, former CEO of Cybin Inc., as Corporate Advisor to advance the development of BETR-001 for non-psychiatric indications including cluster headache and migraine. This appointment brings significant pharmaceutical leadership experience to help advance BetterLife's neurological disorder treatments.
What is the main announcement in this content?
BetterLife Pharma has appointed Doug Drysdale, former CEO of Cybin Inc., as Corporate Advisor to advance the development of BETR-001 for non-psychiatric indications including cluster headache and migraine.
Who is Doug Drysdale and what is his background?
Doug Drysdale is the former CEO of Cybin Inc. who led the company from molecule inception to Phase 3 trials in three years, and previously served as Founding CEO of Alvogen where he grew the company to $500 million in revenues across 35 countries in 5.5 years.
What is BETR-001 and what conditions is it being developed to treat?
BETR-001 is BetterLife’s patented stereoisomer of 2-bromo-LSD, a non-hallucinogenic derivative of LSD, being developed for treatment of cluster headache, migraine, and neuropathic pain.
Why is Doug Drysdale’s appointment significant for BetterLife Pharma?
He brings over 35 years of pharmaceutical leadership experience with multiple successful transactions and has demonstrated ability to rapidly advance drug development programs, having taken Cybin from inception to Phase 3 trials in just three years.
What makes BETR-001 unique compared to traditional LSD?
BETR-001 is non-hallucinogenic, non-controlled, unregulated, and can be self-administered, with previous forms of 2-bromo-LSD shown to be safe and tolerable in humans while reducing cluster headache frequency.
What is the current development status of BETR-001?
BETR-001 is currently in preclinical and IND-enabling studies, with patent protection for synthesis and pending composition and method of use patents covering treatment of various neurological disorders until around 2042.
What other drug candidates does BetterLife Pharma have?
BetterLife also owns a drug candidate for the treatment of viral infections and is seeking strategic alternatives for its further development.
Who is the CEO of BetterLife Pharma and what did they say about this appointment?
Dr. Ahmad Doroudian is the CEO of BetterLife Pharma, who expressed excitement about welcoming Doug Drysdale, describing him as a globally recognized leader and strategist with extensive experience across various markets and indications.
How can investors or interested parties get more information about BetterLife Pharma?
Contact David Melles, Investor Relations Manager, at [email protected] or 1-778-887-1928, or visit the BetterLife Pharma website for further information.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at NewMediaWire
Article Control ID: 260604